Arcus Biosciences Capital Expenditures (CapEx) Growth & History (RCUS)
Arcus Biosciences's capital expenditures (capex) was $2.0M for fiscal 2025.
View full Arcus Biosciences company overviewArcus Biosciences annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.0M | −$4.0M | −66.67% |
| 2024 | 2024-12-31 | $6.0M | −$18.0M | −75.00% |
| 2023 | 2023-12-31 | $24.0M | $18.0M | +300.00% |
| 2022 | 2022-12-31 | $6.0M | −$20.0M | −76.92% |
| 2021 | 2021-12-31 | $26.0M | $23.0M | +766.67% |
| 2020 | 2020-12-31 | $3.0M | $1.1M | +55.84% |
| 2019 | 2019-12-31 | $1.9M | −$1.8M | −48.57% |
| 2018 | 2018-12-31 | $3.7M | −$1.8M | −32.12% |
| 2017 | 2017-12-31 | $5.5M | $1.4M | +34.52% |
| 2016 | 2016-12-31 | $4.1M | — | — |
Arcus Biosciences quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | −$1.0M | — |
| Q4 2025 | 2025-12-31 | $1.0M | $0 | 0.00% |
| Q3 2025 | 2025-09-30 | $0 | −$1.0M | — |
| Q2 2025 | 2025-06-30 | $0 | $0 | — |
| Q1 2025 | 2025-03-31 | $1.0M | −$3.0M | −75.00% |
| Q4 2024 | 2024-12-31 | $1.0M | −$5.0M | −83.33% |
| Q3 2024 | 2024-09-30 | $1.0M | −$9.0M | −90.00% |
| Q2 2024 | 2024-06-30 | $0 | −$5.0M | — |
| Q1 2024 | 2024-03-31 | $4.0M | $1.0M | +33.33% |
| Q4 2023 | 2023-12-31 | $6.0M | $6.0M | — |
| Q3 2023 | 2023-09-30 | $10.0M | $8.0M | +400.00% |
| Q2 2023 | 2023-06-30 | $5.0M | $4.0M | +400.00% |
| Q1 2023 | 2023-03-31 | $3.0M | $0 | 0.00% |
| Q4 2022 | 2022-12-31 | $0 | −$8.4M | — |
| Q3 2022 | 2022-09-30 | $2.0M | −$5.9M | −74.55% |
| Q2 2022 | 2022-06-30 | $1.0M | −$5.1M | −83.53% |
| Q1 2022 | 2022-03-31 | $3.0M | −$641,000 | −17.61% |
| Q4 2021 | 2021-12-31 | $8.4M | $7.0M | +475.68% |
| Q3 2021 | 2021-09-30 | $7.9M | $6.8M | +633.71% |
| Q2 2021 | 2021-06-30 | $6.1M | $5.8M | +2272.27% |
| Q1 2021 | 2021-03-31 | $3.6M | $3.4M | +1642.11% |
| Q4 2020 | 2020-12-31 | $1.5M | $1.3M | +646.94% |
| Q3 2020 | 2020-09-30 | $1.1M | $521,000 | +94.73% |
| Q2 2020 | 2020-06-30 | $256,000 | −$295,000 | −53.54% |
| Q1 2020 | 2020-03-31 | $209,000 | −$419,000 | −66.72% |
| Q4 2019 | 2019-12-31 | $196,000 | −$62,000 | −24.03% |
| Q3 2019 | 2019-09-30 | $550,000 | −$577,000 | −51.20% |
| Q2 2019 | 2019-06-30 | $551,000 | −$753,000 | −57.75% |
| Q1 2019 | 2019-03-31 | $628,000 | −$426,000 | −40.42% |
| Q4 2018 | 2018-12-31 | $258,000 | −$36,000 | −12.24% |
| Q3 2018 | 2018-09-30 | $1.1M | $288,000 | +34.33% |
| Q2 2018 | 2018-06-30 | $1.3M | −$938,000 | −41.84% |
| Q1 2018 | 2018-03-31 | $1.1M | −$1.1M | −50.72% |
| Q4 2017 | 2017-12-31 | $294,000 | — | — |
| Q3 2017 | 2017-09-30 | $839,000 | — | — |
| Q2 2017 | 2017-06-30 | $2.2M | — | — |
| Q1 2017 | 2017-03-31 | $2.1M | — | — |
Arcus Biosciences capital expenditures (capex) trends
Over the last five fiscal years, Arcus Biosciences's capital expenditures (capex) decreased from $3.0M to $2.0M, a change of −$1.0M. The latest reported quarter, Q2 2026, shows $0.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcus Biosciences source filings ↗